These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21962879)

  • 21. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
    Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
    Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
    de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
    Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asymptomatic prostatic inflammation in men with clinical BPH and erectile dysfunction affects the positive predictive value of prostate-specific antigen.
    Agnihotri S; Mittal RD; Kapoor R; Mandhani A
    Urol Oncol; 2014 Oct; 32(7):946-51. PubMed ID: 24996777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
    Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
    Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study.
    Lewandowski J; Sinski M; Symonides B; Korecki J; Rogowski K; Judycki J; Sieczych A; Możeńska O; Gaciong Z
    Urology; 2013 Sep; 82(3):660-5. PubMed ID: 23987161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
    Salah Azab S; Elsheikh MG
    Aging Male; 2015 Jun; 18(2):89-92. PubMed ID: 25295872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D Deficiency as a Potential Marker of Benign Prostatic Hyperplasia.
    Zhang W; Zheng X; Wang Y; Xiao H
    Urology; 2016 Nov; 97():212-218. PubMed ID: 27327576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re: Liao et al.: Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. (Urology 2011;78:1373-1379).
    Mandal S; Patil SB; Goel A
    Urology; 2012 May; 79(5):1192; author reply 1192-3. PubMed ID: 22546407
    [No Abstract]   [Full Text] [Related]  

  • 37. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG; Kaminetsky JC; Auerbach SM; Montelongo RM; Elion-Mboussa A; Viktrup L
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of high bladder neck elevation with urodynamic bladder outlet obstruction in patients with lower urinary tract symptoms and benign prostatic hyperplasia.
    Kang M; Kim M; Choo MS; Bae J; Ku JH; Yoo C; Oh SJ
    Urology; 2014 Dec; 84(6):1461-6. PubMed ID: 25432841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of ultrasound-guided transrectal ethanol injection for the treatment of benign prostatic hyperplasia in patients with high-risk comorbidities: a long-term study at a single tertiary care institution.
    Li Y; Zhao Q; Dong L
    Urology; 2014 Mar; 83(3):586-91. PubMed ID: 24581519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia.
    Favilla V; Cimino S; Castelli T; Madonia M; Barbagallo I; Morgia G
    BJU Int; 2010 Dec; 106(11):1700-3. PubMed ID: 20575982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.